Epic Gold Corp announced significant progress at its Hawkins Project in Ontario, revealing that multiple gold and base metal occurrences may form a large district-scale mineralized system. Recent surface sampling returned high-grade gold assays up to 72.1 g/t, validating historical data and expanding priority targets. The company has secured an Early Exploration Permit and plans Phase I diamond drilling to test extensions of known mineralization and new discoveries, with an updated Mineral Resource Estimate for the McKinnon Gold Zone expected by November 2026. This integrated approach aims to unlock the broader potential of the underexplored Kabinakagami Greenstone Belt.
Epic Gold's recent exploration update coincides with a Basic Materials sector where 27 of 38 US stocks traded on Pluang rose as of Oct 07, 2026 03:12 WIB. For readers following Basic Materials, here is Pluang's market snapshot: Aspen Aerogels Inc (ASPN) rose 2.11% to USD 5.81 with a typical hold time of 13 days; Agnico Eagle Mines Ltd (AEM) increased 1.99% to USD 186.98 with a typical hold time of 56 days and a Pluang order activity of 52% Buy; Linde PLC (LIN) gained 1.97% to USD 491.90 with a typical hold time of 88 days and a Pluang order activity of 45% Buy.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
